SPC327
Sacúbitríl/valsartan, sem sacúbitríl valsartan natríumsaltflétta, þ.e. [((S)-N-valerýl-N-{[2'-(1H-tetrasól-5-ýl)-bífenýl-4-ýl]-metýl}-valín) ((2R,4S)-5-bífenýl-4-ýl-4-(3-karboxý-própíónýlamínó)-2-metýl-pentanósýru etýl ester)]Na3 x H2O, þar sem x er 0 til 3
Status:
AfturkölluðApplication date:
14.1.2021Application published:
15.2.2021
Max expiry date:
22.11.2030Next due date:
30.11.2026Medicine name:
EntrestoMedicine for children:
No
Timeline
Today
14.1.2021Application
15.2.2021Publication
22.11.2030Expires
Marketing license
IS authorization number:
EU/1/15/1058/001; EU/1/15/1058/002-004; EU/1/15/1058/005-007Date:
11.12.2015
Foreign authorization number:
EU/1/15/1058Date:
19.11.2015
Owner
Name:
Novartis Pharma AGAddress:
Lichtstrasse 35, Basel CH
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113 Reykjavík
Patent
Number:
EP2340828